H1 Report 2019

Two companies that truly believe that innovation should be the basis of all the research join forces together. We are going to bring these innovations to patients all over the world: this is something we can be very proud of.

Financial highlights

Group revenues

€108.5 million

At a glance

Cash position

€1147.9 million

At a glance

Letter from the management

Together with Gilead, we announced a transformational global R&D collaboration. This is about maximizing innovation based on the identification and development of new mode of action medicines.
Onno van de Stolpe, CEO
Letter from the management